Elite Pharmaceuticals Inc (ELTP)

[kayak_wench]

When Carter joined Elite it was a company brining a novel product to market that looked like could become a big revenue ticket. Now Elite is developing as typical generic pharmaceutical company. There is little to no chance of a big run the best we can hope for is a slow building of share value over time. Carter probably wanted to be part of an exciting company with big potential like Elite used to be, one developing novel drugs with the potential to make massive money.

I'm not selling at these prices which I may come to regret but I think Nasrat is taking the very conservative route so we shouldn't lose everything. Rate of return will likely be relatively small and slow. Our biggest problem right now is we don't have a product in the known lineup that can spur revenue growth enough to interest investors. The other CNS product will not be taken seriously until some news of its development is released.